Literature DB >> 19651626

Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data.

E I Benchimol1, A Guttmann, A M Griffiths, L Rabeneck, D R Mack, H Brill, J Howard, J Guan, T To.   

Abstract

OBJECTIVE: Health administrative databases can be used to track chronic diseases. The aim of this study was to validate a case ascertainment definition of paediatric-onset inflammatory bowel disease (IBD) using administrative data and describe its epidemiology in Ontario, Canada.
METHODS: A population-based clinical database of patients with IBD aged <15 years was used to define cases, and patient information was linked to health administrative data to compare the accuracy of various patterns of healthcare use. The most accurate algorithm was validated with chart data of children aged <18 years from 12 medical practices. Administrative data from the period 1991-2008 were used to describe the incidence and prevalence of IBD in Ontario children. Changes in incidence were tested using Poisson regression.
RESULTS: Accurate identification of children with IBD required four physician contacts or two hospitalisations (with International Classification of Disease (ICD) codes for IBD) within 3 years if they underwent colonoscopy and seven contacts or three hospitalisations within 3 years in those without colonoscopy (children <12 years old, sensitivity 90.5%, specificity >99.9%; children <15 years old, sensitivity 89.6%, specificity >99.9%; children <18 years old, sensitivity 91.1%, specificity 99.5%). Age- and sex-standardised prevalence per 100 000 population of paediatric IBD has increased from 42.1 (in 1994) to 56.3 (in 2005). Incidence per 100 000 has increased from 9.5 (in 1994) to 11.4 (in 2005). Statistically significant increases in incidence were noted in 0-4 year olds (5.0%/year, p = 0.03) and 5-9 year olds (7.6%/year, p<0.0001), but not in 10-14 or 15-17 year olds.
CONCLUSION: Ontario has one of the highest rates of childhood-onset IBD in the world, and there is an accelerated increase in incidence in younger children.

Entities:  

Mesh:

Year:  2009        PMID: 19651626     DOI: 10.1136/gut.2009.188383

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  117 in total

1.  Laparoscopic adult colorectal surgeon and adolescents with inflammatory bowel disease: a safe combination?

Authors:  Edward D Courtney; Mary Brennan; Gabriele Noble-Jamieson; Rob Heuschkel; R Justin Davies
Journal:  Int J Colorectal Dis       Date:  2010-10-05       Impact factor: 2.571

Review 2.  Natural history of pediatric-onset inflammatory bowel disease: a systematic review.

Authors:  Bincy P Abraham; Seema Mehta; Hashem B El-Serag
Journal:  J Clin Gastroenterol       Date:  2012-08       Impact factor: 3.062

Review 3.  The global burden of IBD: from 2015 to 2025.

Authors:  Gilaad G Kaplan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-09-01       Impact factor: 46.802

Review 4.  The epidemiology and risk factors of inflammatory bowel disease.

Authors:  Yulan Ye; Zhi Pang; Weichang Chen; Songwen Ju; Chunli Zhou
Journal:  Int J Clin Exp Med       Date:  2015-12-15

5.  Use of exclusive enteral nutrition is just as effective as corticosteroids in newly diagnosed pediatric Crohn's disease.

Authors:  Jason Soo; Bushra A Malik; Justine M Turner; Rabin Persad; Eytan Wine; Kerry Siminoski; Hien Q Huynh
Journal:  Dig Dis Sci       Date:  2013-09-12       Impact factor: 3.199

6.  Loss of n-6 fatty acid induced pediatric obesity protects against acute murine colitis.

Authors:  Dorottya Nagy-Szakal; Sabina A V Mir; R Alan Harris; Scot E Dowd; Takeshi Yamada; H Daniel Lacorazza; Nina Tatevian; C Wayne Smith; Edwin F de Zoeten; John Klein; Richard Kellermayer
Journal:  FASEB J       Date:  2015-04-22       Impact factor: 5.191

Review 7.  Diagnosis and management of inflammatory bowel disease in children.

Authors:  Stephanie B Oliveira; Iona M Monteiro
Journal:  BMJ       Date:  2017-05-31

8.  A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.

Authors:  Elaheh Vahabnezhad; Shervin Rabizadeh; Marla C Dubinsky
Journal:  Inflamm Bowel Dis       Date:  2014-04       Impact factor: 5.325

9.  Development and validation of an administrative case definition for inflammatory bowel diseases.

Authors:  Ali Rezaie; Hude Quan; Richard N Fedorak; Remo Panaccione; Robert J Hilsden
Journal:  Can J Gastroenterol       Date:  2012-10       Impact factor: 3.522

10.  Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin: a population-based epidemiological study.

Authors:  Tonya Adamiak; Dorota Walkiewicz-Jedrzejczak; Daryl Fish; Christopher Brown; Jeanne Tung; Khalid Khan; William Faubion; Roger Park; Janice Heikenen; Michael Yaffee; Maria T Rivera-Bennett; Marcy Wiedkamp; Michael Stephens; Richard Noel; Melodee Nugent; Justin Nebel; Pippa Simpson; Michael D Kappelman; Subra Kugathasan
Journal:  Inflamm Bowel Dis       Date:  2013-05       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.